GSK plc (NYSE:GSK) is one of the 12 best healthcare stocks to buy now. On June 12, the company announced licensing its Shigella vaccine candidate to Bharat Biotech.

GSK said it licensed its Shigella vaccine candidate, altaltSonflex1-2-3, to Bharat Biotech International. The U.K. pharma company on Thursday said the agreement paves the way for the development ...

Valneva ( ($VALN) ) just unveiled an update. On July 11, 2025, Valneva announced that the European Medicines Agency (EMA) lifted the temporary ...

As such, the development of Shigella vaccines has been identified as a priority by the World Health Organization (WHO) 2 and, in line with our mission of developing vaccines against infectious ...

S4V2 (Shigella Vaccine) Shigella4V2 is in Phase 2 infant safety and immunogenicity trials in Kenya under a collaboration with LimmaTech.

BactiVac showcases expertise at the World Vaccine Congress 2025, championing global equity and innovation in bacterial vaccine development.

GSK plc (NYSE:GSK) is one of the 12 best healthcare stocks to buy now. On June 12, the company announced licensing its Shigella vaccine candidate to Bharat Biotech. The licensing is part of the ...

This includes the only Lyme disease vaccine candidate in advanced clinical development, which is partnered with Pfizer, the world’s most clinically advanced Shigella vaccine candidate, as well ...

GSK Licenses Shigella Vaccine Candidate to Bharat Biotech Published: June 12, 2025, 4:48 a.m. ET Share Resize ...